131 related articles for article (PubMed ID: 34727304)
1. High-throughput virtual screening and preclinical analysis identifies CB-1, a novel potent dual B-Raf/c-Raf inhibitor, effective against wild and mutant variants of B-Raf expression in colorectal carcinoma.
Al Shahrani M; Abohassan M; Y Alshahrani M; Hakami AR; Rajagopalan P
J Comput Aided Mol Des; 2021 Dec; 35(12):1165-1176. PubMed ID: 34727304
[TBL] [Abstract][Full Text] [Related]
2. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
3. CB-RAF600E-1 exerts efficacy in vemurafenib-resistant and non-resistant-melanoma cells via dual inhibition of RAS/RAF/MEK/ERK and PI3K/Akt signaling pathways.
Al Shahrani M; Rajagopalan P; Abohassan M; Alshahrani M; Alraey Y
Saudi J Biol Sci; 2022 Jun; 29(6):103285. PubMed ID: 35592740
[TBL] [Abstract][Full Text] [Related]
4. Computational high-throughput screening and
Tobeigei FH; Gahtani RM; Shaikh A; Al Ali A; Kameli N; Kamli H; Rajagopalan P
Oncol Res; 2021; 29(5):305-318. PubMed ID: 37305163
[TBL] [Abstract][Full Text] [Related]
5. AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status.
Ma R; Xu L; Qu X; Che X; Zhang Y; Fan Y; Li C; Guo T; Hou K; Hu X; Drew L; Shen M; Cheung T; Liu Y
Br J Cancer; 2018 May; 118(11):1453-1463. PubMed ID: 29755114
[TBL] [Abstract][Full Text] [Related]
6. Identification and Characterization of Small-Molecule Inhibitors to Selectively Target the DFG-in over the DFG-out Conformation of the B-Raf Kinase V600E Mutant in Colorectal Cancer.
Yao H; Sun Q; Zhu J
Arch Pharm (Weinheim); 2016 Oct; 349(10):808-815. PubMed ID: 27624806
[TBL] [Abstract][Full Text] [Related]
7. Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.
Hirschi B; Gallmeier E; Ziesch A; Marschall M; Kolligs FT
Mol Cancer; 2014 May; 13():122. PubMed ID: 24885690
[TBL] [Abstract][Full Text] [Related]
8. Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies.
Fu Y; Wang Y; Wan S; Li Z; Wang G; Zhang J; Wu X
Molecules; 2017 Mar; 22(4):. PubMed ID: 28353640
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
Hong SP; Ahn SK
Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
[TBL] [Abstract][Full Text] [Related]
10. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Wang H; Quan H; Lou L
Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
[TBL] [Abstract][Full Text] [Related]
11. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf
Wang GM; Wang X; Zhu JM; Guo BB; Yang Z; Xu ZJ; Li B; Wang HY; Meng LH; Zhu WL; Ding J
Acta Pharmacol Sin; 2017 Jul; 38(7):1059-1068. PubMed ID: 28414204
[TBL] [Abstract][Full Text] [Related]
12. Electrostatic mechanism of V600E mutation-induced B-Raf constitutive activation in colorectal cancer: molecular implications for the selectivity difference between type-I and type-II inhibitors.
Liu T; Wang Z; Guo P; Ding N
Eur Biophys J; 2019 Jan; 48(1):73-82. PubMed ID: 30218115
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-Raf(V600E) inhibitors.
Li X; Shen J; Tan L; Zhang Z; Gao D; Luo J; Cheng H; Zhou X; Ma J; Ding K; Lu X
Bioorg Med Chem Lett; 2016 Jun; 26(12):2760-2763. PubMed ID: 27155899
[TBL] [Abstract][Full Text] [Related]
14. A selective cellular screening assay for B-Raf and c-Raf kinases.
Ish T; Sootome H; Yagi Y; Yamashita K; Noumi T; Noro N; Ishii T
J Biomol Screen; 2007 Sep; 12(6):818-27. PubMed ID: 17517901
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities.
El-Damasy AK; Lee JH; Seo SH; Cho NC; Pae AN; Keum G
Eur J Med Chem; 2016 Jun; 115():201-16. PubMed ID: 27017549
[TBL] [Abstract][Full Text] [Related]
16. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
[TBL] [Abstract][Full Text] [Related]
17. Helix-Coil Transition Signatures B-Raf V600E Mutation and Virtual Screening for Inhibitors Directed Against Mutant B-Raf.
Bandaru S; Sumithnath TG; Sharda S; Lakhotia S; Sharma A; Jain A; Hussain T; Nayarisseri A; Singh SK
Curr Drug Metab; 2017 Jul; 18(6):527-534. PubMed ID: 28472910
[TBL] [Abstract][Full Text] [Related]
18. B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells.
Herr R; Köhler M; Andrlová H; Weinberg F; Möller Y; Halbach S; Lutz L; Mastroianni J; Klose M; Bittermann N; Kowar S; Zeiser R; Olayioye MA; Lassmann S; Busch H; Boerries M; Brummer T
Cancer Res; 2015 Jan; 75(1):216-29. PubMed ID: 25381152
[TBL] [Abstract][Full Text] [Related]
19. Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib.
Cheng H; Chang Y; Zhang L; Luo J; Tu Z; Lu X; Zhang Q; Lu J; Ren X; Ding K
J Med Chem; 2014 Mar; 57(6):2692-703. PubMed ID: 24588073
[TBL] [Abstract][Full Text] [Related]
20. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
